RT Journal Article
SR Electronic
T1 Inflammasome activation and pulmonary viral loads define two distinct clinical outcomes in COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.06.24.22276878
DO 10.1101/2022.06.24.22276878
A1 de Sá, Keyla S.G.
A1 Amaral, Luana A.
A1 Caetano, Camila C.S.
A1 Becerra, Amanda
A1 Batah, Sabrina S.
A1 de Oliveira, Isadora M.
A1 Lopes, Letícia S.
A1 Almeida, Leticia
A1 Oliveira, Samuel
A1 Wada, Danilo Tadao
A1 Koenigkam-Santos, Marcel
A1 Martins, Ronaldo B.
A1 Rosales, Roberta R. C.
A1 Arruda, Eurico
A1 Fabro, Alexandre T
A1 Zamboni, Dario S.
YR 2023
UL http://medrxiv.org/content/early/2023/02/17/2022.06.24.22276878.abstract
AB COVID-19 has affected more than half a billion people worldwide, with more than 6.3 million deaths, but the pathophysiological mechanisms involved in lethal cases and the host determinants that determine the different clinical outcomes are still unclear. In this study, we assessed lung autopsies of 47 COVID-19 patients and examined the inflammatory profiles, viral loads, and inflammasome activation. Additionally, we correlated these factors with the patient’s clinical and histopathological conditions. Robust inflammasome activation, mediated by macrophages and endothelial cells, was detected in the lungs of lethal cases of SARS-CoV-2. An analysis of gene expression allowed for the classification of COVID-19 patients into two different clusters. Cluster 1 died with higher viral loads and exhibited a reduced inflammatory profile than Cluster 2. Illness time, mechanical ventilation time, pulmonary fibrosis, respiratory functions, histopathological status, thrombosis, viral loads and inflammasome activation significantly differed between the two clusters. Our data demonstrated two distinct profiles in lethal cases of COVID-19, thus indicating that the balance of viral replication and inflammasome-mediated pulmonary inflammation led to different clinical outcomes. We provide important information to understand clinical variations in severe COVID-19, a process that is critical for decisions between immune-mediated or antiviral-mediated therapies for the treatment of critical cases of COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding: Fundacao de Amparo a Pesquisa do Estado de Sao Paulo, FAPESP grants 2013/08216-2, 2019/11342-6 and 2020/04964-8. Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, CNPq grant 303021/2020-9. Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior, CAPES grant 88887.507253/2020-00.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Research Ethics Committee of FMRP/USP.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors